Clinical Trial Update: Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients

View source ↗

Summary

Completed clinical trial evaluating Tissue Factor Pathway Inhibitor (TFPI) for haemorrhagic manifestations in Hemophilia A and Hemophilia B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Tissue Factor Pathway Inhibitor (TFPI) (Tissue Factor Pathway Inhibitor)

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Hemophilia | Status: COMPLETED